Trupanion, Inc.
TRUP Nasdaq Hospital & Medical Service Plans Financials FY2016βFY2025
What Trupanion, Inc. does
No business description yet.
- Legal name
- TRUPANION, INC.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Feb 13, 2026
- Accession Β· CIK
- 0001371285-26-000018
0001371285
Revenue and margins
Trupanion, Inc. had $1.4B of revenue in fiscal 2025, up 11.9% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $75.4M in fiscal 2025, 5.2% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Trupanion, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 3.3%.
Balance sheet
Cash, debt and the ratios that show how comfortably Trupanion, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $213M | $222M | $277M | $307M | $371M |
| Debt incl. finance leases | $0.0M | $68.4M | $128M | $128M | $102M |
| Net debt / EBITDA | β | β | β | β25.9x | β9.1x |
| Debt / equity | 0.0x | 0.2x | 0.4x | 0.4x | 0.3x |
| Interest coverage | β3,519.6x | β10.1x | β3.4x | β0.7x | 1.0x |
| Current ratio | 1.7x | 1.6x | 1.6x | 1.7x | 1.7x |
| Quick ratio | 1.7x | 1.6x | 1.6x | 1.7x | 1.7x |
| Total assets | $563M | $672M | $783M | $807M | $915M |
| Total liabilities | $230M | $366M | $479M | $484M | $531M |
| Shareholders' equity | $332M | $305M | $304M | $323M | $384M |
| Net debt (β = net cash) | β$213M | β$154M | β$150M | β$180M | β$269M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 9 | 4 / 9 | 4 / 9 | 4 / 9 | 3 / 9 | 2 / 9 | 5 / 9 | 7 / 9 | 6 / 9 |
| Accruals ratio | β14.5% | β11.9% | β8.7% | β7.7% | β7.2% | β8.1% | β5.9% | β8.7% | β7.3% | β8.1% |
| Altman Z'' | 0.27 | 0.69 | 2.11 | 1.77 | 4.05 | 2.31 | 1.37 | 1.24 | 1.72 | 2.14 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $188M | $243M | $304M | $384M | $502M | $699M | $905M | $1.1B | $1.3B | $1.4B |
| Gross profit | $33.3M | $43.1M | $51.4M | $64.9M | $81.9M | $104M | $122M | $131M | $179M | $231M |
| Operating income | β$6.7M | β$2.6M | β$1.0M | β$1.9M | β$4.9M | β$35.2M | β$43.0M | β$40.7M | β$9.5M | $13.8M |
| Interest expense | $0.2M | $0.5M | $1.2M | $1.3M | $1.4M | $0.0M | $4.3M | $12.1M | $14.5M | $13.8M |
| Pretax income | β$6.9M | β$1.9M | β$0.9M | β$1.6M | β$5.7M | β$35.2M | β$44.2M | β$45.0M | β$9.6M | $22.0M |
| Income tax | $0.0M | β$0.4M | β$0.0M | $0.2M | $0.1M | $0.3M | $0.5M | β$0.3M | β$0.0M | $2.6M |
| Net income | β$6.9M | β$1.5M | β$0.9M | β$1.8M | β$5.8M | β$35.5M | β$44.7M | β$44.7M | β$9.6M | $19.4M |
| Net income to common | β$6.9M | β$1.5M | β$0.9M | β$1.8M | β$5.8M | β$35.5M | β$44.7M | β$44.7M | β$9.6M | $19.4M |
| Diluted EPS | β$0.24 | β$0.05 | β$0.03 | β$0.05 | β$0.16 | β$0.89 | β$1.10 | β$1.08 | β$0.23 | $0.45 |
| Diluted shares | 0.03B | 0.03B | 0.03B | 0.03B | 0.04B | 0.04B | 0.04B | 0.04B | 0.04B | 0.04B |
| Cash flow | ||||||||||
| Cash from operations | $5.0M | $9.7M | $12.7M | $16.2M | $21.5M | $7.5M | β$8.0M | $18.6M | $48.3M | $89.5M |
| Capital expenditure | $1.9M | $3.1M | $56.9M | $5.4M | $7.5M | $12.4M | $17.1M | $18.3M | $9.7M | $14.1M |
| Free cash flow | $3.1M | $6.5M | β$44.3M | $10.8M | $14.1M | β$4.9M | β$25.1M | $0.4M | $38.6M | $75.4M |
| Depreciation and amortization | $3.8M | $4.2M | $4.5M | $5.6M | $7.1M | $12.0M | $10.9M | $12.5M | $16.5M | $15.8M |
| Stock-based compensation | $2.9M | $3.4M | $4.8M | $6.8M | $8.9M | $28.2M | $33.4M | $33.2M | $33.4M | $38.3M |
| Acquisitions | β | β | β | $0.0M | $48.1M | $0.0M | $15.0M | $0.0M | $0.0M | β |
| Share buybacks | β | β | β | β | β | $0.0M | $5.8M | $0.0M | $0.0M | β |
| Dividends and buybacks | β | β | β | β | β | $0.0M | $5.8M | $0.0M | $0.0M | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $53.2M | $63.3M | $81.1M | $98.9M | $230M | $213M | $222M | $277M | $307M | $371M |
| Total debt | $4.8M | $9.3M | $12.9M | $26.1M | $0.0M | $0.0M | $68.4M | $128M | $128M | $102M |
| Current assets | $65.4M | $86.6M | $118M | $159M | $337M | $391M | $469M | $562M | $597M | $691M |
| Current liabilities | $30.4M | $45.9M | $63.2M | $91.6M | $150M | $224M | $290M | $344M | $350M | $410M |
| Property and equipment, net | $8.5M | $7.9M | $69.8M | $70.4M | $72.6M | $78.0M | $90.7M | $104M | $102M | $105M |
| Goodwill | β | β | β | $0.0M | $33.0M | $32.7M | $42.0M | $43.7M | $37.0M | $39.4M |
| Intangible assets | $4.9M | $5.0M | $8.1M | $7.7M | $27.1M | $22.7M | $24.0M | $18.7M | $13.2M | $24.1M |
| Total assets | $82.3M | $106M | $208M | $257M | $498M | $563M | $672M | $783M | $807M | $915M |
| Total liabilities | $37.6M | $57.4M | $78.3M | $120M | $158M | $230M | $366M | $479M | $484M | $531M |
| Shareholders' equity | $44.7M | $48.4M | $129M | $137M | $340M | $332M | $305M | $304M | $323M | $384M |
| Margins | ||||||||||
| Gross margin | 17.7% | 17.7% | 16.9% | 16.9% | 16.3% | 14.9% | 13.5% | 11.8% | 13.9% | 16.1% |
| Operating margin | β3.6% | β1.1% | β0.3% | β0.5% | β1.0% | β5.0% | β4.8% | β3.7% | β0.7% | 1.0% |
| EBITDA margin | β1.5% | 0.7% | 1.1% | 1.0% | 0.4% | β3.3% | β3.5% | β2.5% | 0.5% | 2.1% |
| Net margin | β3.7% | β0.6% | β0.3% | β0.5% | β1.2% | β5.1% | β4.9% | β4.0% | β0.7% | 1.4% |
| FCF margin | 1.6% | 2.7% | β14.6% | 2.8% | 2.8% | β0.7% | β2.8% | 0.0% | 3.0% | 5.2% |
| Returns | ||||||||||
| Return on capital | β | β | β1.4% | β2.4% | β3.5% | β23.4% | β22.5% | β20.8% | β5.2% | 10.6% |
| Return on capital employed | β12.9% | β4.4% | β0.7% | β1.2% | β1.4% | β10.4% | β11.3% | β9.3% | β2.1% | 2.7% |
| Return on equity | β15.4% | β3.2% | β1.0% | β1.4% | β2.5% | β10.6% | β14.0% | β14.7% | β3.1% | 5.5% |
| Return on assets | β8.4% | β1.6% | β0.6% | β0.8% | β1.5% | β6.7% | β7.2% | β6.1% | β1.2% | 2.3% |
| Return on tangible equity | β17.3% | β3.5% | β0.8% | β1.4% | β2.1% | β12.8% | β18.7% | β18.5% | β3.5% | 6.1% |
| Growth | ||||||||||
| Revenue growth | β | 28.9% | 25.3% | 26.3% | 30.8% | 39.2% | 29.5% | 22.5% | 16.0% | 11.9% |
| FCF growth | β | 113.2% | β777.2% | β | 30.7% | β134.7% | β | β | 10,674.0% | 95.4% |
| Share count change | β | 3.7% | 8.0% | 8.4% | 3.5% | 11.9% | 1.6% | 1.6% | 1.7% | 3.3% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β33.9x | β19.7x | β19.6x | β107.2x | β | β | β | β25.9x | β9.1x |
| Debt / equity | 0.1x | 0.2x | 0.1x | 0.2x | 0.0x | 0.0x | 0.2x | 0.4x | 0.4x | 0.3x |
| Interest coverage | β30.7x | β5.0x | β0.9x | β1.4x | β3.6x | β3,519.6x | β10.1x | β3.4x | β0.7x | 1.0x |
| Current ratio | 2.2x | 1.9x | 1.9x | 1.7x | 2.2x | 1.7x | 1.6x | 1.6x | 1.7x | 1.7x |
| Quick ratio | 2.2x | 1.9x | 1.9x | 1.7x | 2.2x | 1.7x | 1.6x | 1.6x | 1.7x | 1.7x |
| Capital allocation | ||||||||||
| Capex / revenue | 1.0% | 1.3% | 18.7% | 1.4% | 1.5% | 1.8% | 1.9% | 1.6% | 0.8% | 1.0% |
| Stock comp / revenue | 1.6% | 1.4% | 1.6% | 1.8% | 1.8% | 4.0% | 3.7% | 3.0% | 2.6% | 2.7% |
| Payouts / FCF | β | β | β | β | β | β | β | 0.0% | 0.0% | β |
| Quality scores | ||||||||||
| Piotroski F-score | β | 5.0 | 4.0 | 4.0 | 4.0 | 3.0 | 2.0 | 5.0 | 7.0 | 6.0 |
| Altman Z'' | 0.3 | 0.7 | 2.1 | 1.8 | 4.0 | 2.3 | 1.4 | 1.2 | 1.7 | 2.1 |
| Accruals ratio | β14.5% | β11.9% | β8.7% | β7.7% | β7.2% | β8.1% | β5.9% | β8.7% | β7.3% | β8.1% |
Source: SEC EDGAR XBRL filings (CIK 0001371285). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.